Related Experiment Video
Updated: Apr 12, 2026
05:06
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
2.6K
Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill"
S Srinivasan1,2,3,4, J C Florez3,5,6,4
1Pediatric Endocrine Unit, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
Clinical Pharmacology and Therapeutics
|May 15, 2015
Summary
Preventing type 2 diabetes is crucial. While lifestyle changes are best, pharmacological options like metformin show promise for effective, sustainable prevention, unlike other drugs with limited benefits or side effects.
Area of Science:
- Endocrinology
- Public Health
- Pharmacology
Background:
- Type 2 diabetes presents a significant global health challenge.
- Lifestyle interventions are effective but face sustainability and resource limitations.
- Developing accessible and effective prevention strategies is a public health priority.
Purpose of the Study:
- To review evidence on pharmacological agents for type 2 diabetes prevention.
- To identify medications that are efficacious, well-tolerated, and cost-effective.
- To assess the feasibility of pharmacotherapy as a sustainable prevention strategy.
Main Methods:
- Systematic review of existing literature on diabetes prevention medications.
- Analysis of efficacy, adherence, tolerability, and cost-effectiveness data.
- Comparison of metformin with other pharmacological agents.
Main Results:
- Metformin demonstrates efficacy and tolerability for type 2 diabetes prevention.
- Most alternative pharmacological options show limited efficacy or significant side effects.
- Lifestyle modification remains a cornerstone but is resource-intensive.
Conclusions:
- Metformin is a viable pharmacological option for type 2 diabetes prevention.
- Further research into cost-effective and well-tolerated medications is warranted.
- A combination of strategies may be necessary for widespread diabetes prevention.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
984
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
984
01:27Peripheral Artery Disease III: Interprofessional Care
606
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
606
01:22Diabetes Mellitus: Type 2 and Gestational
5.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.8K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K